Bio
Born in Scotland, Dr. Ashley graduated with 1st class Honors in Physiology and Medicine from the University of Glasgow. He completed medical residency and a PhD in molecular physiology at the University of Oxford before moving to Stanford University where he trained in cardiology and advanced heart failure, joining the faculty in 2006. His group is focused on the science of precision medicine. In 2010, he led the team that carried out the first clinical interpretation of a human genome. The article became one of the most cited in clinical medicine that year and was later featured in the Genome Exhibition at the Smithsonian in DC. Over the following 3 years, the team extended the approach to the first whole genome molecular autopsy, to a family of four, and to a case series of patients in primary care. They now routinely apply genome sequencing to the diagnosis of patients at Stanford hospital where Dr Ashley directs the Clinical Genome Program and the Center for Inherited Cardiovascular Disease. Dr Ashley was the first co-chair of the steering committee of the NIH Undiagnosed Diseases Network. He was a recipient of the National Innovation Award from the American Heart Association and the NIH Director?s New Innovator Award. He is part of the winning team of the $75m One Brave Idea competition and co-founder of three companies: Personalis Inc ($PSNL), Deepcell Inc, and SVExa Inc. He was recognized by the Obama White House for his contributions to Personalized Medicine and in 2018 was awarded the American Heart Association Medal of Honor for Genomic and Precision Medicine. He was appointed Associate Dean in 2019. Father to three young Americans, in his ?spare? time, he tries to understand American football, plays the saxophone, and conducts research on the health benefits of single malt Scotch whisky.
Clinical Focus
- Cardiology
- Inherited cardiovascular disease
- Hypertrophic Cardiomyopathy
- Cardiomyopathy, Dilated
- Heart Failure
- Arrhythmogenic Right Ventricular Dysplasia
- Sports Cardiology
- Left ventricular non-compaction cardiomyopathy
- Genomic medicine
- Undiagnosed disease
Academic Appointments
-
Professor - Med Center Line, Medicine - Cardiovascular Medicine
-
Professor - Med Center Line, Genetics
-
Professor - Med Center Line, Biomedical Data Science
-
Professor - Med Center Line (By courtesy), Pathology
-
Member, Bio-X
-
Member, Cardiovascular Institute
-
Faculty Affiliate, Institute for Human-Centered Artificial Intelligence (HAI)
Administrative Appointments
-
Co-Director, Stanford Center for Digital Health (2017 - Present)
-
Co-Director, Stanford Data Science Initiative (2016 - Present)
-
Co-chair, NIH Undiagnosed Diseases Network (2014 - 2017)
-
Director, Stanford Clinical Genomics Program (2013 - Present)
-
Founding Director, Stanford Center for Inherited Cardiovascular Disease (2010 - Present)
-
Co-Director, Stanford Research Training Program in Myocardial Biology (T32) (2010 - Present)
-
Director, Stanford Cardiopulmonary Exercise Testing Laboratory (2007 - Present)
-
Co-chair, Cardiovascular Working Group, Clinical Genome Resource (Clingen) (2014 - 2016)
-
Leadership committee, AHA Council on Functional Genomics and Translational Biology (2009 - 2014)
-
Member, Institute of Medicine Roundtable on Translating Genomic-based Research for Health (2012 - 2015)
Honors & Awards
-
Medal of Honor (Genomic and Precision Medicine), American Heart Association (2018)
-
One Brave Idea, American Heart Association (2017)
-
Fellow, Royal College of Physicians (London) (2017)
-
Fellow, American Society of Clinical Investigation (2016)
-
NIH Director's New Innovator Award, National Institutes of Health (2009)
-
Faculty Scholar, Donald E. and Delia B. Baxter Foundation (2009)
-
Fellow, American Heart Association (2009)
-
Innovative Research Award, American Heart Association (2008)
-
Career Development Award (K08), National Institutes of Health (2006)
-
Western Affiliates Young Investigator Award, American Heart Association (2004)
-
Cardiovascular Medicine Basic Science Award, Stanford University (2004)
-
Young Investigator Award (Basic), Astra-Zeneca (2003)
-
Young Investigator Prize in Cardiovascular Medicine, UK Medical Research Society (2002)
-
Young Investigator Award, European Society of Cardiology (2002)
Professional Education
-
Board Certification: Royal College of Physicians-U.K., Cardiology (1999)
-
Residency: University of Oxford (1996) UK
-
Internship: University of Glasgow (1997) Scotland
-
Medical Education: University of Glasgow (1996) Scotland
-
Fellowship: University of Oxford (2002) UK
-
Fellowship: Stanford University Medical Center (2006) CA
-
DPhil, University of Oxford, Molecular Cardiology (2002)
-
MRCP (UK), Royal College of Physicians (UK), Medicine (1999)
-
MB ChB, University of Glasgow, Medicine (1996)
-
BSc (Hons), University of Glasgow, Physiology (1993)
Community and International Work
-
Arbor Free Cardiology Clinic
Location
Bay Area
Ongoing Project
Yes
Opportunities for Student Involvement
Yes
Patents
-
Ashley EA, Quertermous T, Grube E. "United States Patent 12,074,964 Developing biologically active agents that modulate activity of restenosis target gene, comprises combining candidate biologically active agent, and determining the effect of agent on restenosis associated molecular and cellular changes", The Board of Trustees of the Leland Stanford Junior University, Mar 7, 2008
-
Ashley EA, Chen MM, Quertermous T. "United States Patent 11,985,460 Apelin and uses thereof", The Board of Trustees of the Leland Stanford Junior University, Nov 14, 2007
-
Vailaya A, Kuchinsky A, King JY, Ferrara R, Quertermous T, Vairaya A, Ashley IA, Katermas T, Ashley EA. "United States Patent 10,641,492 Significant molecules identification method for biological network used in disease analysis, involves calculating connectivity score for molecule represented by identified node based on significance scores of each node", Agilent Technologies, Inc., Jul 26, 2007
-
Deng D, Tsalenko A, Ben-Dor A, Yakhini ZH, Quertermous T, Ashley EA, Yang E, Tabibiazar R, Tsao P. "United States Patent 11,412,437 New composition comprising a targeting agent that is conjugated to a functional moiety and that selectively binds to a polypeptide encoded by a DEA gene, useful in treating or preventing atherosclerosis", Agilent Technologies, Inc., Apr 27, 2006
-
Ben-Dor A, Bruhn L, Deng D, Tsalenko A, Ashley EA, Chen MC, Quertermous T, Yakhini Z, Chen MM, Deng DX. "United States Patent 7,947,280 New composition having a targeting agent selectively binding to a polypeptide encoded by an upregulated-in-recovery (UIR) or downregulated-in-recovery (DIR) gene, useful for diagnosing, preventing and/or treating heart failure", The Board of Trustees of the Leland Stanford Junior University, Jul 14, 2005